Orthofix Medical Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Orthofix Medical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Orthofix Medical stock.
View analyst ratings for Orthofix Medical or view top-rated stocks.

1 Wall Street research analysts have issued 1 year target prices for Orthofix Medical's stock. Their OFIX stock forecasts range from $45.00 to $45.00. On average, they anticipate Orthofix Medical's stock price to reach $45.00 in the next year. This suggests a possible upside of 91.1% from the stock's current price.
View analysts' price targets for Orthofix Medical or view top-rated stocks among Wall Street analysts.

Orthofix Medical's stock was trading at $31.09 at the beginning of the year. Since then, OFIX shares have decreased by 24.3% and is now trading at $23.55.
View the best growth stocks for 2022 here.

Orthofix Medical is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for Orthofix Medical.

Orthofix Medical Inc. (NASDAQ:OFIX) released its earnings results on Friday, May, 6th. The medical device company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.18 by $0.28. The medical device company earned $106.42 million during the quarter, compared to the consensus estimate of $104.70 million. Orthofix Medical had a positive trailing twelve-month return on equity of 3.34% and a negative net margin of 7.96%.
View Orthofix Medical's earnings history.

Orthofix Medical issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share (EPS) guidance of $0.58-$0.73 for the period, compared to the consensus earnings per share estimate of $0.66. The company issued revenue guidance of $475.00 million-$490.00 million, compared to the consensus revenue estimate of $481.93 million.

32 employees have rated Orthofix Medical CEO Brad Mason on Glassdoor.com. Brad Mason has an approval rating of 73% among Orthofix Medical's employees.

Some companies that are related to Orthofix Medical include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX).
View all of OFIX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthofix Medical investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Edwards Lifesciences (EW), Gilead Sciences (GILD), Biogen (BIIB), Pfizer (PFE), Exxon Mobil (XOM), Advanced Micro Devices (AMD), bluebird bio (BLUE) and Esperion Therapeutics (ESPR).

Orthofix Medical trades on the NASDAQ under the ticker symbol "OFIX."

Orthofix Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.25%), Vanguard Group Inc. (10.80%), Paradice Investment Management LLC (5.06%), State Street Corp (3.98%), Polar Asset Management Partners Inc. (3.70%) and Dimensional Fund Advisors LP (3.37%). Company insiders that own Orthofix Medical stock include Brad Mason, Catherine M Burzik, James F Hinrichs, Jon Carl Serbousek, Kimberley A Elting, Michael E Paolucci, Rice Doug and Ronald A Matricaria.
View institutional ownership trends for Orthofix Medical.

OFIX stock was sold by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., Arrowstreet Capital Limited Partnership, State Street Corp, State of New Jersey Common Pension Fund D, Royce & Associates LP, Gabelli Funds LLC, Gabelli Funds LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Orthofix Medical or view top insider-selling stocks.

OFIX stock was bought by a variety of institutional investors in the last quarter, including Endurant Capital Management LP, Heartland Advisors Inc., Dimensional Fund Advisors LP, Victory Capital Management Inc., Paradigm Capital Management Inc. NY, First Eagle Investment Management LLC, BlackRock Inc., and Engineers Gate Manager LP. Company insiders that have bought Orthofix Medical stock in the last two years include Catherine M Burzik, Jon Carl Serbousek, Kimberley A Elting, Michael E Paolucci, and Rice Doug.
View insider buying and selling activity for Orthofix Medical or or view top insider-buying stocks.

Shares of OFIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OFIX stock can currently be purchased for approximately $23.55.

Orthofix Medical (NASDAQ:OFIX) has a market capitalization of $468.93 million and generates $464.48 million in revenue each year. The medical device company earns $-38.38 million in net income (profit) each year or ($1.860010) on an earnings per share basis.

Orthofix Medical employs 1,087 workers across the globe.

Orthofix Medical was founded in 1980.

Orthofix Medical's mailing address is 3451 Plano Parkway, Lewisville TX, 75056. The official website for Orthofix Medical is www.orthofix.com. The medical device company can be reached via phone at (214) 937-2000, via email at [email protected], or via fax at 599 9 461 6978.